Literature DB >> 12243462

Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs.

D Zemke1, B Yamini, V Yuzbasiyan-Gurkan.   

Abstract

Mast cell tumors are among the most commonly seen tumors of the skin in dogs and are more highly aggressive than mast cell tumors of other species. Some breeds display a markedly higher incidence of mast cell tumor development than others and appear to have some genetic predisposition. Recently, mutations have been found in canine mast cell tumor tissues and cell lines within the juxtamembrane domain of the protooncogene c-KIT In previous studies utilizing a small number of cases, no association between the presence of a mutation and the breed of dog or grade of the tumor could be identified. An expanded study with a larger sample set was performed to explore this possibility. The juxtamembrane domain of c-KIT was amplified using the polymerase chain reaction from genomic DNA preparations of 88 paraffin-embedded mast cell tumors from selected breeds. Mutations, consisting of duplications and deletions, were found in 12 of the tumors. A significant association was found between the presence of a mutation and a higher grade of tumor but not between breed and grade or between breed and the presence of a mutation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12243462     DOI: 10.1354/vp.39-5-529

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  43 in total

1.  AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit.

Authors:  Tzu-Yin Lin; Joelle Fenger; Sridhar Murahari; Misty D Bear; Samuel K Kulp; Dasheng Wang; Ching-Shih Chen; William C Kisseberth; Cheryl A London
Journal:  Blood       Date:  2010-03-16       Impact factor: 22.113

2.  Immunohistochemical evaluation of AKT protein activation in canine mast cell tumours.

Authors:  S Rodriguez; K Fadlalla; T Graham; B Tameru; C D Fermin; T Samuel
Journal:  J Comp Pathol       Date:  2012-01-30       Impact factor: 1.311

3.  Generation and characterization of novel canine malignant mast cell line CL1.

Authors:  Tzu-Yin Lin; Rachael Thomas; Pei-Chien Tsai; Matthew Breen; Cheryl A London
Journal:  Vet Immunol Immunopathol       Date:  2008-10-11       Impact factor: 2.046

Review 4.  Systemic mastocytosis with subcutaneous hemorrhage and edema in a Greyhound dog: case report and review of diagnostic criteria.

Authors:  Alexander Aceino; Unity Jeffery; Julie Piccione; Carolyn L Hodo
Journal:  J Vet Diagn Invest       Date:  2020-11-09       Impact factor: 1.279

5.  KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.

Authors:  Cheryl A London; Heather L Gardner; Sarah Rippy; Gerald Post; Krista La Perle; Linda Crew; Lori Lopresti-Morrow; Andrew J Garton; Gerald McMahon; Theresa M LaVallee; Richard Gedrich
Journal:  Clin Cancer Res       Date:  2016-11-04       Impact factor: 12.531

6.  Identification of a novel point mutation of mouse proto-oncogene c-kit through N-ethyl-N-nitrosourea mutagenesis.

Authors:  Hai-Bin Ruan; Nian Zhang; Xiang Gao
Journal:  Genetics       Date:  2005-02       Impact factor: 4.562

7.  Genomic profiling of canine mast cell tumors identifies DNA copy number aberrations associated with KIT mutations and high histological grade.

Authors:  Hiroyuki Mochizuki; Rachael Thomas; Scott Moroff; Matthew Breen
Journal:  Chromosome Res       Date:  2017-01-05       Impact factor: 5.239

8.  In vitro chemosensitivity of canine mast cell tumors grades II and III to all-trans-retinoic acid (ATRA).

Authors:  K C Pinello; M Nagamine; T C Silva; P Matsuzaki; H V Caetano; L N Torres; H Fukumasu; J L Avanzo; J M Matera; M L Z Dagli
Journal:  Vet Res Commun       Date:  2009-01-14       Impact factor: 2.459

9.  Canine and human gastrointestinal stromal tumors display similar mutations in c-KIT exon 11.

Authors:  Emmalena Gregory-Bryson; Elizabeth Bartlett; Matti Kiupel; Schantel Hayes; Vilma Yuzbasiyan-Gurkan
Journal:  BMC Cancer       Date:  2010-10-15       Impact factor: 4.430

10.  Ex vivo evaluation of imatinib mesylate for induction of cell death on canine neoplastic mast cells with mutations in c-Kit exon 11 via apoptosis.

Authors:  Giacomo Rossi; Chiara Bertani; Subeide Mari; Carlotta Marini; Giacomo Renzoni; Gregory Ogilvie; Gian Enrico Magi
Journal:  Vet Res Commun       Date:  2013-01-13       Impact factor: 2.459

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.